BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and Peptides in the Limelight: US FDA May Ease Restrictions on Several Peptides The Dermatology Digest The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and